| 2023-12-14 |
复牌提示：
2023-12-13 19:50:00 停牌，复牌日期 2023-12-15 00:00:01
|
| 2023-11-01 |
详情>>
股本变动：
变动后总股本18866.27万股
|
| 2023-11-01 |
详情>>
业绩披露：
2023年三季报(累计)每股收益-3.21美元,归母净利润-6.02亿美元,同比去年增长-30.28%
|
| 2023-11-01 |
财报披露：
美东时间 2023-11-01 盘前发布财报
|
| 2023-08-02 |
详情>>
业绩披露：
2023年中报每股收益-2.06美元,归母净利润-3.86亿美元,同比去年增长-42.36%
|
| 2023-04-27 |
详情>>
业绩披露：
2023年一季报每股收益-0.93美元,归母净利润-1.75亿美元,同比去年增长-28.02%
|
| 2023-04-24 |
股东大会：
将于2023-05-30召开股东大会
会议内容 ▼▲
- 1.Consider and vote on a proposal to adopt the Agreement and Plan of Merger (as it may be amended or supplemented from time to time, the “merger agreement”), dated March 12, 2023, by and among Seagen, Pfizer Inc. (“Pfizer”), and Aris Merger Sub, Inc., a wholly-owned subsidiary of Pfizer (“Merger Sub”), a copy of which is included as Annex A to the proxy statement of which this notice forms a part, and pursuant to which Merger Sub will be merged with and into Seagen, with Seagen surviving the merger as a wholly-owned subsidiary of Pfizer (the “merger,” and such proposal the “merger agreement proposal”);
2.Consider and vote on a proposal to approve, on a non-binding, advisory basis, certain compensation arrangements for Seagen’s named executive officers in connection with the merger (the “compensation proposal”).
|
| 2023-04-18 |
股东大会：
将于2023-05-31召开股东大会
会议内容 ▼▲
- 1.Elect the three nominees for Class I director named in the accompanying proxy statement to hold office until Seagen’s 2026 Annual Meeting of Shareholders
2.Approve, on an advisory basis, the compensation of Seagen’s named executive officers as disclosed in the accompanying proxy statement
3.Indicate, on an advisory basis, the preferred frequency of shareholder advisory votes on the compensation of Seagen’s named executive officers
4.Approve the amendment and restatement of the Seagen Inc. Amended and Restated 2007 Equity Incentive Plan to, among other things, increase the aggregate number of shares of common stock authorized for issuance thereunder by 5,190,000 shares
5.Ratify the appointment of PricewaterhouseCoopers LLP as Seagen’s independent registered public accounting firm for the fiscal year ending December 31, 2023
|
| 2023-02-15 |
详情>>
业绩披露：
2022年年报每股收益-3.3美元,归母净利润-6.1亿美元,同比去年增长9.51%
|
| 2023-02-15 |
详情>>
业绩披露：
2020年年报每股收益3.51美元,归母净利润6.14亿美元,同比去年增长486.81%
|
| 2022-10-27 |
详情>>
业绩披露：
2022年三季报(累计)每股收益-2.51美元,归母净利润-4.62亿美元,同比去年增长7.54%
|
| 2022-07-28 |
详情>>
业绩披露：
2021年中报每股收益-1.14美元,归母净利润-2.06亿美元,同比去年增长-8.65%
|
| 2022-07-28 |
详情>>
业绩披露：
2022年中报每股收益-1.48美元,归母净利润-2.71亿美元,同比去年增长-31.71%
|
| 2022-04-28 |
详情>>
业绩披露：
2022年一季报每股收益-0.74美元,归母净利润-1.36亿美元,同比去年增长-12.41%
|
| 2022-03-30 |
股东大会：
将于2022-05-13召开股东大会
会议内容 ▼▲
- 1.Elect the two nominees for Class III director named in the accompanying proxy statement to hold office until Seagen’s 2025 Annual Meeting of Shareholders
2.Approve, on an advisory basis, the compensation of Seagen’s named executive officers as disclosed in the accompanying proxy statement
3.Ratify the appointment of PricewaterhouseCoopers LLP as Seagen’s independent registered public accounting firm for the fiscal year ending December 31, 2022
|
| 2022-02-09 |
详情>>
业绩披露：
2021年年报每股收益-3.7美元,归母净利润-6.74亿美元,同比去年增长-209.91%
|
| 2021-10-28 |
详情>>
业绩披露：
2021年三季报(累计)每股收益-2.75美元,归母净利润-5亿美元,同比去年增长-211.93%
|
| 2021-09-06 |
温馨提示：
美股因劳工节，9月6日休市一天
|
| 2021-03-31 |
股东大会：
将于2021-05-14召开股东大会
会议内容 ▼▲
- 1.Elect the three nominees for Class II director named in the accompanying proxy statement to hold office until Seagen’s 2024 Annual Meeting of Shareholders.
2.Approve, on an advisory basis, the compensation of Seagen’s named executive officers as disclosed in the accompanying proxy statement.
3.Ratify the appointment of PricewaterhouseCoopers LLP as Seagen’s independent registered public accounting firm for the fiscal year ending December 31, 2021.
4.Transact such other business as may properly come before the Annual Meeting and any adjournment or postponement thereof.
|
| 2020-04-01 |
股东大会：
将于2020-05-15召开股东大会
会议内容 ▼▲
- 1.Elect the three nominees for Class I director named in the accompanying proxy statement to hold office until Seattle Genetics’ 2023 Annual Meeting of Shareholders.
2.Approve, on an advisory basis, the compensation of Seattle Genetics’ named executive officers as disclosed in the accompanying proxy statement.
3.Approve the amendment and restatement of the Seattle Genetics, Inc. Amended and Restated 2007 Equity Incentive Plan to, among other things, increase the aggregate number of shares of common stock authorized for issuance thereunder by 6,000,000 shares.
4.Ratify the appointment of PricewaterhouseCoopers LLP as Seattle Genetics’ independent registered public accounting firm for the fiscal year ending December 31, 2020.
5.Transact such other business as may properly come before the Annual Meeting and any adjournment or postponement thereof.
|
| 2019-04-04 |
股东大会：
将于2019-05-20召开股东大会
会议内容 ▼▲
- 1.To elect the three nominees for Class III director named in the accompanying proxy statement to hold office until the Company’s 2022 Annual Meeting of Stockholders.
2.To ratify the appointment of PricewaterhouseCoopers LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2019.
3.To approve the amendment and restatement of the Seattle Genetics, Inc. Amended and Restated 2000 Employee Stock Purchase Plan, or the ESPP, to increase the aggregate number of shares of common stock authorized for issuance thereunder by 1,000,000 shares and to allow for the participation in the ESPP by our non-U.S. based employees.
4.To approve, on an advisory basis, the compensation of the Company’s named executive officers as disclosed in the accompanying proxy statement.
5.To transact such other business as may properly come before the Annual Meeting and any adjournment or postponement thereof.
|
| 2018-07-09 |
详情>>
内部人交易：
SIEGALL CLAY B共交易4笔
|
| 2018-04-04 |
股东大会：
将于2018-05-18召开股东大会
会议内容 ▼▲
- 1.To elect the three nominees for Class II director named in the accompanying proxy statement to hold office until the Company’s 2021 Annual Meeting of Stockholders.
2.To ratify the appointment of PricewaterhouseCoopers LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2018.
3.To approve the amendment and restatement of the Seattle Genetics, Inc. Amended and Restated 2007 Equity Incentive Plan to, among other changes, increase the aggregate number of shares of common stock authorized for issuance thereunder by 6,000,000 shares.
4.To approve, on an advisory basis, the compensation of the Company’s named executive officers as disclosed in the accompanying proxy statement.
5.To transact such other business as may properly come before the Annual Meeting and any adjournment or postponement thereof.
|
| 2017-04-05 |
股东大会：
将于2017-05-19召开股东大会
会议内容 ▼▲
- 1. To elect the two nominees for Class I director named in the accompanying proxy statement to hold office until the Company’s 2020 Annual Meeting of Stockholders.
2. To ratify the appointment of PricewaterhouseCoopers LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2017.
3. To approve, on an advisory basis, the compensation of the Company’s named executive officers as disclosed in the accompanying proxy statement.
4. To indicate, on an advisory basis, the preferred frequency of stockholder advisory votes on the compensation of the Company’s named executive officers.
5. To transact such other business as may properly come before the Annual Meeting and any adjournment or postponement thereof.
|
| 2016-04-06 |
股东大会：
将于2016-05-20召开股东大会
会议内容 ▼▲
- 1. To elect the three nominees for Class III director named in the accompanying proxy statement to hold office until the Company’s 2019 Annual Meeting of Stockholders.
2. To approve the amendment and restatement of the Seattle Genetics, Inc. Amended and Restated 2007 Equity Incentive Plan to increase the aggregate number of shares of common stock authorized for issuance thereunder by 6,000,000 shares and to approve the award limits and other terms applicable to awards intended to qualify as “performance-based compensation” for purposes of Section 162(m) of the Internal Revenue Code.
3. To ratify the appointment of PricewaterhouseCoopers LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2016.
4. To approve, on an advisory basis, the compensation of the Company’s named executive officers as disclosed in the accompanying proxy statement.
5. To transact such other business as may properly come before the Annual Meeting and any adjournment or postponement thereof.
|
| 2015-04-06 |
股东大会：
将于2015-05-15召开股东大会
会议内容 ▼▲
- 1. To elect the three nominees for Class II director named in the accompanying proxy statement to hold office until the Company’s 2018 Annual Meeting of Stockholders.
2. To approve the amendment and restatement of the Seattle Genetics, Inc. Amended and Restated 2000 Employee Stock Purchase Plan to increase the aggregate number of shares of common stock authorized for issuance thereunder by 1,000,000 shares.
3. To ratify the appointment of PricewaterhouseCoopers LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2015.
4. To approve, on an advisory basis, the compensation of the Company’s named executive officers as disclosed in the accompanying proxy statement.
5. To transact such other business as may properly come before the Annual Meeting and any adjournment or postponement thereof.
|
| 2014-04-07 |
股东大会：
将于2014-05-16召开股东大会
会议内容 ▼▲
- 1. To elect the four nominees for director named in the accompanying proxy statement to hold office until the Company’s 2017 Annual Meeting of Stockholders.
2. To approve the amendment and restatement of the Seattle Genetics, Inc. Amended and Restated 2007 Equity Incentive Plan to increase the aggregate number of shares of common stock authorized for issuance thereunder by 4,500,000 shares and to make certain other changes thereto as described in the accompanying proxy statement.
3. To ratify the appointment of PricewaterhouseCoopers LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2014.
4. To approve, on an advisory basis, the compensation of the Company’s named executive officers as disclosed in the accompanying proxy statement.
5. To transact such other business as may properly come before the Annual Meeting and any adjournment or postponement thereof.
|